This announcement which has been prepared by, and is the sole responsibility of, the Directors of the Company is intended for distribution in the
United Kingdomonly and solely to existing shareholders in the Company pursuant to the ISDX rules in relation to the Circular published On 11 April 2014by the Company and the shareholder resolutions described in that document. This announcement is not a prospectus or an admission document, and investors should not purchase or subscribe for any securities referred to in this announcement except solely on the basis of information in any Admission Document as may subsequently be published by the Company in due course in connection with the proposed admission of the shares to trading on AIM, a market operated by the London Stock Exchange plc. This announcement does not constitute, or form part of, any offer, invitation or promotion to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract therefore. Union Medtech plc ("Union Medtech" or "the Company") Result of General Meeting 30 April 2014Union Medtech plc, an ISDX Growth Market investment company adopted by current management in 2012 as a vehicle to seek opportunities in the medical technology sector, announces that at the General Meeting of the Company, held yesterday, all resolutions were duly passed. The General Meeting follows the issue of a Circular by the Company on 11th April 2014, and confirms shareholder approval for a share consolidation, the proposed acquisition of REX Bionics Limited("REX Bionics"), a developer and manufacturer of REX, a hands-free robotic exoskeleton for use by wheelchair users, and proposed placing to raise up to £10 Million, and other proposals in relation to the Company's intention to move to the AIM market of the London Stock Exchange. For further information please contact: Union Medtech plc Peter Worrall, Chief Financial Officer Tel: +44 (0)1428 645416 ISDX Corporate Adviser Peterhouse Corporate Finance Fungai Ndoro/ Eran Zucker+44 (0) 20 7469 0932 Oriel Securities Limited(Financial Adviser) Juliet Thompson/ Jonathan Senior+44 (0) 20 77107600 Consilium Strategic Communications Mary-Jane Elliott/ Emma Thompson/ Jessica Hodgson/ Lindsey Nevilleunionmedtech@consilium-comms.com Tel +44 203 709 5700 This announcement is not for publication or distribution, in whole or in part, directly or indirectly, in or into the United States, Australia, New Zealand, Canada, Japanor any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein should inform themselves of and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This announcement is not directed to or intended for use by, distribution or transfer, either directly or indirectly to, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, transfer, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. In particular, neither this announcement nor any copy of it may be sent, or taken, transmitted or distributed, directly or indirectly, in or into Australia, New Zealand, Canada, Japan, or the United States(including its territories and dependencies, any state of the United Statesand the District of Columbia) or to any resident of Australia, New Zealand, Canada, Japanor the United States. This announcement is only being made to persons outside of the United Statesin reliance on exemptions from the US Securities Act of 1933, as amended (the "Securities Act"). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein or as may be offered following this announcement have not been, and will not be, registered under the Securities Act. They may not be offered, sold, transferred, distributed or delivered, directly or indirectly within, into or in the United Statesexcept pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of the securities will take place in the United States. Neither the US Securities and Exchange Commissionnor any securities regulatory authority of any state or other jurisdiction of the United Stateshas approved or disapproved of an investment in the securities or passed on the accuracy or adequacy of the contents of this announcement. Any representation to the contrary is a criminal offence in the United States. Any placing in connection with any such admission will only involve (i) in the United Kingdom, persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended or otherwise falling within certain exemptions under that Order, and (ii) in any member state of the European Economic Area other than the United Kingdom, "qualified investors" within the meaning of article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC). END The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.